Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 298,468 shares, a decrease of 63.9% from the June 15th total of 826,117 shares. Based on an average trading volume of 309,898 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.9% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Heights Capital Management Inc. acquired a new stake in shares of Nyxoah in the 4th quarter valued at $3,575,000. Deutsche Bank AG boosted its holdings in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Nyxoah in the third quarter worth about $98,000. Bank of America Corp DE increased its position in Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock worth $91,000 after purchasing an additional 12,012 shares during the period. Finally, Raymond James Financial Inc. raised its holdings in Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NYXH shares. Robert W. Baird set a $2.85 target price on shares of Nyxoah in a research note on Thursday, July 9th. Weiss Ratings downgraded shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Nyxoah in a research report on Monday, March 23rd. Stifel Nicolaus decreased their price objective on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, June 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $7.00 price objective (down from $9.00) on shares of Nyxoah in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.96.

Nyxoah Price Performance

NASDAQ NYXH traded down $0.06 on Tuesday, hitting $1.58. 282,958 shares of the company were exchanged, compared to its average volume of 166,458. The firm has a 50 day moving average of $2.23 and a two-hundred day moving average of $3.38. The company has a market cap of $61.24 million, a P/E ratio of -0.64 and a beta of 1.61. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. Nyxoah has a 1-year low of $1.26 and a 1-year high of $8.59.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.11. Nyxoah had a negative net margin of 543.21% and a negative return on equity of 163.73%. The firm had revenue of $7.38 million during the quarter, compared to analysts’ expectations of $7.05 million. On average, equities analysts predict that Nyxoah will post -1.67 EPS for the current year.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.